Cargando…
Immunotherapy in metastatic prostate cancer
INTRODUCTION: Prostate cancer remains a challenge as a target for immunological approaches. The approval of the first cell-based immune therapy, Sipuleucel-T for prostate cancer introduced prostate cancer as a solid tumor with the potential to be influenced by the immune system. METHODS: We reviewed...
Autor principal: | Slovin, Susan F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054656/ https://www.ncbi.nlm.nih.gov/pubmed/27843208 http://dx.doi.org/10.4103/0970-1591.191240 |
Ejemplares similares
-
Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012) -
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
por: Slovin, Susan F
Publicado: (2013) -
Malignant priapism in metastatic prostate cancer: A late event occurring early
por: Barrett-Campbell, Odeth, et al.
Publicado: (2018) -
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021) -
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)